Previous 10 | Next 10 |
Meridian Bioscience (NASDAQ: VIVO ): Q3 Non-GAAP EPS of $0.13 beats by $0.04 ; GAAP EPS of $0.10 beats by $0.02 . Revenue of $50.8M (-4.3% Y/Y) beats by $0.23M . Shares -3% PM. Press Release More news on: Meridian Bioscience, Inc., Earnings news and commentary, Healthcare stoc...
CINCINNATI, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2019. Fourth Quarter 2019 Highlights (Comparison to Fourth Quarter Fiscal 2018): Consolidated revenue d...
CINCINNATI, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2019 financial results Thursday, November 7, 2019. Jack Kenny, Chief Executive Office...
Below are the five companies in the Health Care Supplies industry with the highest forward earnings yields. Using projected earnings for the current fiscal year, the forward earnings yield is useful to compare a stock's return vs. owning a similar stock or other yield assets (e.g. bonds). Gene...
Meridian Bioscience, Inc. (VIVO) Q3 2019 Earnings Conference Call July 30, 2019, 10:00 ET Company Participants Bryan Baldasare - Interim CFO & CAO John Kenny - President & CEO Conference Call Participants Andrew Brackmann - William Blair & Company William Quirk ...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2019 Q3 earnings Read more ...
Meridian Bioscience (NASDAQ: VIVO ): Q3 Non-GAAP EPS of $0.16 beats by $0.07 ; GAAP EPS of $0.12 beats by $0.03 . More news on: Meridian Bioscience, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
CINCINNATI, Ohio, July 30, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter and first nine months ended June 30, 2019. Third Quarter 2019 Highlights (Comparison to Third Quarter Fiscal 2018): Consolidated revenu...
CINCINNATI, July 10, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report third quarter 2019 financial results Tuesday, July 30, 2019. Jack Kenny, Chief Executive Officer, and Bryan Baldas...
Finding Growth In A No-Growth Market With the second quarter earnings cycle underway the question arises, what sectors should dividend growth investors be targeting? Growth in the second quarter is expected to be negative, estimates for future quarters has fallen and there is a risk the ear...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...